Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. 

The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialisation of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications.  

In addition, Insilico and Lilly will collaborate on multiple R&D programmes focused on targets selected by Lilly, by combining Insilico’s Pharma.AI platforms with Lilly’s development capabilities and disease-area expertise. 

Insilico will receive a $115 million upfront payment, followed by development, regulatory, and commercial milestones up to $2.75 billion. 

“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time,” said Alex Zhavoronkov, Founder and CEO of Insilico Medicine. “Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health.” 

“Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas,” added Andrew Adams, Group Vice President of Molecule Discovery at Lilly. “This collaboration allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.” 

The post Eli Lilly and Insilico agree AI-driven drug discovery alliance appeared first on Drug Discovery World (DDW).